GSK3511294 (Depemokimab)

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 3

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

CompletedNCT04719832

GlaxoSmithKlineAsthma

Start: 2021-03-17End: 2023-11-21Updated: 2024-12-17

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

CompletedNCT04718389

GlaxoSmithKlineAsthma

Start: 2021-01-26End: 2025-09-14Updated: 2026-05-18

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

CompletedNCT05243680

GlaxoSmithKlineAsthma

Start: 2022-03-01End: 2025-05-19Updated: 2026-01-15

Related Papers

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps

The Journal of Clinical Pharmacology2026-07-30

Validity, reliability, and longitudinal measurement properties of the Asthma Daytime and Nighttime Symptom Diaries in patients with moderate-to-severe asthma.

2026-05-20

Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis

Frontiers in Allergy2026-03-06

Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.

2025-12-29

Psychometric Evaluation Supports the Validation of the St George's Respiratory Questionnaire in Patients With Asthma With Type 2 Inflammation Receiving Medium-to-High Dose Inhaled Corticosteroids

American Journal of Respiratory and Critical Care Medicine2025-05-01

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

New England Journal of Medicine2024-09-0978 citations